A(

A&B (HK)

Description

A&B (HK)

Investor Profile

A&B (HK) has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B rounds (top funding stages).
  • Majority of deals are located in France.
  • Strong thematic focus on Biopharma, Biotechnology, Pharmaceutical.

Stage Focus

  • Series B (100%)

Country Focus

  • France (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does A&B (HK) frequently co-invest with?

GO CAPITAL
Europe, Bretagne, France, Rennes
Co-Investments: 1
CM
Europe, Cambridgeshire, United Kingdom, Cambridge
Co-Investments: 1
Newton Biocapital
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 1
Anaxago
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Mirae Asset
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Karista
Europe, Ile-de-France, France, Paris
Co-Investments: 1

What are some of recent deals done by A&B (HK)?

Acticor Biotech

Paris, Ile-de-France, France

Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke.

BiopharmaBiotechnologyPharmaceuticalTherapeutics
Series BNov 6, 2019
Amount Raised: $7,749,106